<PAPER><mode2 name='PMC4246671' hasDoc='yes' version='597'></mode2><article xml:lang='en' xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Alzheimers Res Ther</journal-id><journal-id journal-id-type='iso-abbrev'>Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type='epub'>1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4246671</article-id><article-id pub-id-type='publisher-id'>alzrt271</article-id><article-id pub-id-type='doi'>10.1186/alzrt271</article-id><article-categories><subj-group subj-group-type='heading'><subject>Research</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1><CoreSc2 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc2>Cerebral inflammation is an underlying mechanism of early death in Alzheimer’s disease: a 13-year cause-specific multivariate mortality study</s></article-title></title-group><contrib-group><contrib contrib-type='author' id='A1'><name><surname>Nägga</surname><given-names>Katarina</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>Katarina.Nagga@skane.se</email></contrib><contrib contrib-type='author' id='A2'><name><surname>Wattmo</surname><given-names>Carina</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>Carina.Wattmo@skane.se</email></contrib><contrib contrib-type='author' id='A3'><name><surname>Zhang</surname><given-names>Yi</given-names></name><xref rid='I2' ref-type='aff'>2</xref><xref rid='I3' ref-type='aff'>3</xref><email>zhy70@yahoo.com</email></contrib><contrib contrib-type='author' id='A4'><name><surname>Wahlund</surname><given-names>Lars-Olof</given-names></name><xref rid='I2' ref-type='aff'>2</xref><xref rid='I3' ref-type='aff'>3</xref><email>Lars-Olof.Wahlund@ki.se</email></contrib><contrib contrib-type='author' corresp='yes' id='A5'><name><surname>Palmqvist</surname><given-names>Sebastian</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I4' ref-type='aff'>4</xref><email>sebastian.palmqvist@med.lu.se</email></contrib></contrib-group><aff id='I1'><label>1</label>Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden</aff><aff id='I2'><label>2</label>Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden</aff><aff id='I3'><label>3</label>Department of Neurobiology, Care Sciences and Society, Section of Clinical Geriatrics, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden</aff><aff id='I4'><label>4</label>Department of Neurology, Skåne University Hospital, Lund SE-221 85, Sweden</aff><pub-date pub-type='collection'><year>2014</year></pub-date><pub-date pub-type='epub'><day>7</day><month>7</month><year>2014</year></pub-date><volume>6</volume><issue>4</issue><fpage>41</fpage><lpage>41</lpage><history><date date-type='received'><day>30</day><month>12</month><year>2013</year></date><date date-type='accepted'><day>5</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 Nägga et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Nägga et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by/4.0'><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/publicdomain/zero/1.0/'>http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href='http://alzres.com/content/6/4/41'></self-uri><abstract><sec><title>Introduction</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Although Alzheimer’s disease (AD) is associated with early death, its life expectancy differs greatly between patients.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A better understanding of this heterogeneity may reveal important disease mechanisms underlying the malignancy of AD.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> The aim of this study was to examine the relation between AD pathologies and early death in AD caused by dementia.</s></p></sec><sec><title>Methods</title><p><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>At a memory clinic, 247 referred consecutive patients with AD were monitored during 12.6 ± 1.6 years.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Multivariate Cox regression analyses were performed with baseline measures of amyloid beta (Aβ) pathology (<italic>APOE</italic> genotype, cerebrospinal fluid (CSF) Aβ42) tau pathology (CSF phosphorylated tau and total tau), cerebrovascular pathology (white-matter lesions and CSF/serum albumin ratio), neuroinflammatory pathology (CSF soluble vascular cell adhesion molecule-1, sVCAM-1), frontal, temporal, and central brain atrophies, global cognition, sex, and age.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Comorbidities and medications also were analyzed.</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All continuous variables were transformed to <italic>z</italic> scores to compare hazard ratios (HRs) and 95% confidence intervals (CIs).</s></p></sec><sec><title>Results</title><p><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>At follow-up, 89% of the patients had died.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean survival time was 6.4 ± 3.0 years.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The AD pathology that independently predicted an early death caused by dementia was cerebral inflammation (sVCAM-1; HR, 1.32; 95% CI, 1.07–1.64).</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Other independent predictors were lower global cognition (HR, 0.51; 95% CI, 0.43–0.61), frontal atrophy (HR, 1.38; 95% CI, 1.12–1.70), and medial temporal atrophy (HR, 1.23; 95% CI, 1.02–1.49).</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> When examining death caused by dementia and related causes (vascular diseases and infections), age (HR, 1.23; 95% CI, 1.04–1.46) and cerebrovascular pathology (white-matter lesions: HR, 1.17; 95% CI, 1.01–1.36; and CSF/serum albumin ratio: HR, 1.16; 95% CI, 1.001–1.34) were also significant risk factors in addition to the previous variables.</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> No comorbidity or medication was significant in the specific-cause models.</s></p></sec><sec><title>Conclusions</title><p><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>This is the first study to link neuroinflammation independently to early death in AD and, hence, a rapidly progressing disease.</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Frontal and medial temporal atrophies and low cognition were also significant predictors.</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> These are probably downstream biomarkers that reflect neuronal degeneration and late-stage disease.</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Our results suggest that inflammation, and not amyloid or tau pathology, is an independent underlying mechanism in the malignancy of AD.</s></p></sec></abstract></article-meta></front><body><sec sec-type='intro'><title>Introduction</title><p><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Alzheimer’s disease (AD) is strongly associated with an early death, compared with the nondemented elderly population [<xref rid='B1' ref-type='bibr'>1</xref>-<xref rid='B5' ref-type='bibr'>5</xref>].</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recent data from the United States showed that AD accounts for a population-attributable risk between 5% and 15% on 5-year mortality for ages 65 and older, and represents the fifth leading cause of death in the same age range [<xref rid='B6' ref-type='bibr'>6</xref>].</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Even when adjusting for other diseases that are commonly regarded as causes of death, such as cancer or cardiac diseases, AD remains an independent risk factor for early death [<xref rid='B7' ref-type='bibr'>7</xref>,<xref rid='B8' ref-type='bibr'>8</xref>].</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The survival from the time of AD diagnosis varies between 3 and 8 years [<xref rid='B9' ref-type='bibr'>9</xref>,<xref rid='B10' ref-type='bibr'>10</xref>].</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Pneumonia is the most common cause of death in AD in studies using death certificates [<xref rid='B11' ref-type='bibr'>11</xref>], medical records from the institution where the patient died [<xref rid='B12' ref-type='bibr'>12</xref>], and studies based on autopsy for the determination of cause of death [<xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, pneumonia can be considered merely a “symptom” caused by deteriorated health status, dysphagia, malnutrition, or problems with clearing secretions, which is seen in end-stage dementia [<xref rid='B11' ref-type='bibr'>11</xref>,<xref rid='B13' ref-type='bibr'>13</xref>-<xref rid='B15' ref-type='bibr'>15</xref>].</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The question, which has been stated before [<xref rid='B7' ref-type='bibr'>7</xref>], is what mechanisms or pathologies drive the disease rapidly to this end-stage to a greater extent in some patients than in others.</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A better understanding of the heterogeneity of the life expectancy in AD may highlight important pathologic mechanisms of the malignancy of AD and provide a more accurate prognosis for patients.</s></p><p><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>AD is associated with different brain pathologies, such as amyloid beta deposition, tau pathology, vascular lesions, and cerebral inflammation [<xref rid='B16' ref-type='bibr'>16</xref>-<xref rid='B18' ref-type='bibr'>18</xref>].</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The combination of these pathologies differs among patients and can probably explain some of the heterogeneity observed within the spectrum of AD symptoms [<xref rid='B19' ref-type='bibr'>19</xref>].</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Our aim in the present study was to examine whether a certain combination of these pathologies, or the prominence of a specific pathology, can explain the huge difference in life expectancy observed in AD.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Therefore, we investigated the predictive ability of AD pathologies and related factors regarding mortality.</s></p></sec><sec sec-type='methods'><title>Methods</title><sec><title>Subjects</title><p><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>The patients originated from the Malmö Alzheimer Study [<xref rid='B20' ref-type='bibr'>20</xref>].</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> This study consisted of consecutive patients who were referred to the Memory Clinic of the Skåne University Hospital in Malmö, Sweden, because of cognitive complaints.</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Patients who underwent a lumbar puncture (which was part of the clinical routine) and were diagnosed with probable or possible AD [<xref rid='B21' ref-type='bibr'>21</xref>] between 1999 and 2003 were included.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Physicians with experience in dementia disorders assessed the patients, who underwent computed tomography (CT) or magnetic resonance imaging (MRI) of the brain, lumbar puncture, cognitive tests, and blood analysis.</s></p><p><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>The Malmö Alzheimer Study consisted of 259 patients.</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Of these, 12 were excluded from the present study because of missing data; the current study population included 247 patients with a complete data set.</s></p><p><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The patients gave their consent for research, and the study was approved by the Regional Ethics Committee in Lund (2012/461 and 2010/401) and the Swedish National Board of Health and Welfare (58744/2012).</s></p></sec><sec><title>Mortality data</title><p><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The follow-up consisted of a control whether the patient was alive or not in April 2013, and the follow-up time was defined as the duration from the CT/MRI scan to this control.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> If the patient was dead, the specific cause of death was obtained from the Swedish Causes of Death Register.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The cause of death was determined mostly clinically by an attending responsible physician with knowledge of the patient’s medical history, and, in only a few cases, by autopsy.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The causes were specified according to the 10th revision of the International Classification of Disease (ICD-10) [<xref rid='B22' ref-type='bibr'>22</xref>].</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To examine better the pathologies of AD that increase mortality specifically related to AD, the causes of death were divided into three groups based on the diagnoses in the death register.</s></p><p><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Dementia</s></p><p><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>These causes were not restricted to AD (although this was the initial diagnosis), but also included vascular dementia and unspecified dementia (ICD F01, F03, and G30), as some patients acquired other brain pathologies during the time of the study.</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> In these cases, the patient had no other apparent diseases that could have caused death.</s></p><p><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Dementia and related causes</s></p><p><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>In addition to the causes described, this group consisted of cerebrovascular diseases, heart disease, and other vascular diseases; ICD I2X, I4X–I7X), which are risk factors for AD and share the feature of vascular pathology.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Infections (most commonly pneumonia, but also infections related to decubitus and unknown infections) were also included in this group (ICD A41, J18, N39), because aspiration, self-neglect, and sedentary lifestyle are very common consequences of late-AD symptoms.</s></p><p><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>All-cause mortality</s></p><p><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>This group consisted of all available causes of death including those not related to dementia, such as cancer, gastrointestinal diseases, and chronic obstructive pulmonary disease (COPD).</s></p></sec><sec><title>Risk factors for mortality: main analysis</title><p><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The potential risk factors for mortality were chosen based on the known pathologies and biomarkers of AD, and constituted the main analysis.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Only baseline variables were used in the study.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> They were as follows:</s></p><sec><title>Amyloid pathology</title><p><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The 42-amino-acid isoform of amyloid-β<sub>1–42</sub> (Aβ42) in cerebrospinal fluid (CSF) was analyzed with Luminex xMAP technology to assess amyloid burden [<xref rid='B23' ref-type='bibr'>23</xref>].</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The procedures and analysis of the lumbar puncture and CSF analysis followed the Alzheimer’s Association Flow Chart [<xref rid='B24' ref-type='bibr'>24</xref>].</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Another variable that is associated with amyloid deposition is the apolipoprotein E (<italic>APOE</italic>) ϵ4 allele, especially the presence of two alleles.</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> APOE was therefore entered into the model as a dichotomous variable (that is, presence or absence of ϵ4/ϵ4).</s></p></sec><sec><title>Tau pathology</title><p><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The levels of total tau and tau phosphorylated at Thr181 (P-tau) in the CSF were determined to examine tau pathology.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> They were analyzed by using the same method as that used to assess Aβ42.</s></p></sec><sec><title>Cerebrovascular pathology</title><p><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>White-matter lesions in the left and right frontal and parietal-occipital regions, as well as lesions in the left and right basal ganglia, were assessed by using the Age-Related White Matter Changes (ARWMC) scale [<xref rid='B25' ref-type='bibr'>25</xref>].</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The assessment was performed by S.P. by using CT or MRI scans.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The specific procedures, as well as intra- and interrater reliability of this method were published previously [<xref rid='B26' ref-type='bibr'>26</xref>].</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The scores from the different regions were added to obtain a combined score ranging from 0 to 18 points.</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In addition to the ARWMC scale, the CSF/serum albumin ratio (albumin ratio), which is a marker for the integrity of the blood–brain barrier (BBB), also was calculated.</s></p></sec><sec><title>Neuroinflammatory pathology</title><p><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The CSF levels of the soluble vascular cell-adhesion molecule 1 (sVCAM-1) were analyzed as a measure of cerebral inflammation by using a commercially available quantitative enzyme-linked immunosorbent assay (ELISA) kit (R&amp;D Systems, Minneapolis, MN, USA).</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This procedure was described previously [<xref rid='B20' ref-type='bibr'>20</xref>].</s></p></sec><sec><title>Regional atrophy</title><p><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Atrophy is, <italic>per se</italic>, not a pathologic process, but a biomarker of neuronal degeneration, which is a hallmark of AD.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Different cerebral areas are affected in AD, depending on disease type and duration [<xref rid='B27' ref-type='bibr'>27</xref>].</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Atrophy was assessed by an experienced radiologist (Y.Z.) by using linear measurements on CT or MRI scans.</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To include the essential brain regions, the following measures were entered into a Cox regression model: (a) the temporal horn ratio, which measures medial temporal atrophy, (b) Evans ratio, which measures frontal atrophy, and (3) the cella media index, which measures central atrophy.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The details of this procedure were published previously [<xref rid='B28' ref-type='bibr'>28</xref>].</s></p></sec><sec><title>Cognition, sex, and age</title><p><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The Mini-Mental State Examination (MMSE) was used to assess global cognitive function [<xref rid='B29' ref-type='bibr'>29</xref>].</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In addition, sex and age were entered in the models, as both of these characteristics might affect the other independent variables and mortality.</s></p></sec></sec><sec><title>Concomitant diseases and medications: subanalyses</title><p><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Concomitant diseases and medications are potentially influential risk factors for the prediction of mortality caused by AD pathology.</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> These variables were not included in the main Cox regression analysis because of their high number.</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Instead, they were analyzed in separate Cox regression models.</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Data on current medications and comorbidities were collected from information provided by patients and their relatives and from documentation on diseases and drugs in the patients’ medical records.</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Several diseases were grouped in larger categories; ischemic heart disease, congestive heart failure, and arrhythmias were named “heart diseases”; all gastrointestinal diseases were grouped together, as well as all pulmonary diseases.</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Finally, liver and kidney diagnoses were grouped together in one category.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Diagnoses with a frequency smaller than 5% were called “all other diseases.”</s></p><p><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Current medications were grouped together based on mechanism or treatment indication, except for the category cardiovascular drugs, which included all heart-disease indications and antihypertensive treatment, as these often co-occur, and could not be distinguished from each other.</s></p></sec><sec><title>Statistics</title><p><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Cox proportional hazards models were used to estimate separately the effects of the previously mentioned risk factors on the relative risk of time to death (caused by dementia, dementia and related causes, and all-cause mortality).</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All continuous variables followed a normal distribution and were screened for collinearity by using Pearson correlation; the highest correlation coefficient was seen between tau and P-tau (<italic>r</italic> = 0.77).</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To facilitate the comparison of hazard ratios (HRs) in the Cox regression analysis, all continuous variables were converted to <italic>z</italic> scores in the main analyses.</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Thus, the HR corresponded to an increase of 1 standard deviation (SD).</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> This conversion does not affect the model or the significance values of the covariates.</s></p><p><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The dichotomous variables were entered into the model if their prevalence was at least 10%, to avoid unstable estimates and a diminished statistical power.</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> This approach did not affect the main analysis, but excluded the following potential predictors from the subanalyses: diabetes, major depression, liver/kidney disease, and medication with antacids, NSAIDs, or hormone therapy.</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The duration from the date of CT/MRI scan to either death or follow-up (that is, controlling whether the patient was deceased) was used as the time variable.</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The independent variables were entered by using the stepwise backward likelihood ratio (LR) method with an entry limit of <italic>P</italic> = 0.05 and a removal limit of <italic>P</italic> = 0.051, to avoid including nonsignificant variables in the final model.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All analyses were performed with SPSS (IBM Corp.</s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Released 2011.</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> IBM SPSS Statistics for Mac, Version 20.0.</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Armonk, NY, USA).</s></p></sec></sec><sec sec-type='results'><title>Results</title><sec><title>Demographics</title><p><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The demographics of, and variables analyzed in all 247 patients are shown in Table <xref rid='T1' ref-type='table'>1</xref>.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean follow-up time (that is, from CT/MRI scan until the follow-up) was 12.6 years (SD, 1.6 years).</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> At follow-up, 221 (89%) of the 247 patients had died.</s><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean time to death was 6.4 years (SD, 3.0 years).</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The causes of death were specified by 65 different ICD-10 codes.</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> These were grouped into 11 different categories (Figure <xref rid='F1' ref-type='fig'>1</xref>).</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The most common cause was dementia (55%), which was interpreted as an absence of other apparent diseases that could have caused death.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Different cerebrovascular, cardiovascular, and other vascular causes of death were the second largest group (23.1%).</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Infections and cancer were the causes of death in 6.4% and 5.9% of the cases.</s></p><table-wrap position='float' id='T1'><label>Table 1</label><caption><p>Characteristics (variables entered into the Cox Regression Analysis)</p></caption><table border='1' rules='groups' frame='hsides'><colgroup><col align='left'></col><col align='left'></col></colgroup><thead valign='top'><tr><th align='left'><bold>Variable</bold></th><th align='left'><bold>Mean ± SD (</bold><bold><italic>n</italic></bold> <bold>= 247)</bold></th></tr></thead><tbody valign='top'><tr><td valign='bottom' align='left'>Time to death, <italic>n</italic> = 221 (years)<hr></hr></td><td valign='bottom' align='left'>6.4 ± 3.0<hr></hr></td></tr><tr><td valign='bottom' align='left'>Age (years)<hr></hr></td><td valign='bottom' align='left'>75.2 ± 6.1<hr></hr></td></tr><tr><td valign='bottom' align='left'>Sex (female)<hr></hr></td><td valign='bottom' align='left'>69%<hr></hr></td></tr><tr><td valign='bottom' align='left'>MMSE score (0 to 30 points)<hr></hr></td><td valign='bottom' align='left'>21.3 ± 5.1<hr></hr></td></tr><tr><td valign='bottom' align='left'>Temporal horn ratio (medial temporal atrophy)<hr></hr></td><td valign='bottom' align='left'>0.040 ± 0.017<hr></hr></td></tr><tr><td valign='bottom' align='left'>Evans ratio (frontal atrophy)<hr></hr></td><td valign='bottom' align='left'>0.33 ± 0.038<hr></hr></td></tr><tr><td valign='bottom' align='left'>Cella media index (central atrophy)<hr></hr></td><td valign='bottom' align='left'>0.22 ± 0.040<hr></hr></td></tr><tr><td valign='bottom' align='left'>CSF sVCAM-1 (neuroinflammatory pathology, μg/L)<hr></hr></td><td valign='bottom' align='left'>11.7 ± 4.3<hr></hr></td></tr><tr><td valign='bottom' align='left'>ARWMC (cerebrovascular pathology, 0 to 18 points)<hr></hr></td><td valign='bottom' align='left'>3.2 ± 3.4<hr></hr></td></tr><tr><td valign='bottom' align='left'>Albumin ratio (BBB integrity)<hr></hr></td><td valign='bottom' align='left'>0.0075 ± 0.0032<hr></hr></td></tr><tr><td valign='bottom' align='left'>CSF Tau (pg/ml)<hr></hr></td><td valign='bottom' align='left'>619 ± 322<hr></hr></td></tr><tr><td valign='bottom' align='left'>CSF P-tau (pg/ml)<hr></hr></td><td valign='bottom' align='left'>76 ± 31<hr></hr></td></tr><tr><td valign='bottom' align='left'>CSF Aβ42 (pg/ml)<hr></hr></td><td valign='bottom' align='left'>410 ± 99<hr></hr></td></tr><tr><td align='left'>APOE ϵ4/ϵ4</td><td align='left'>22%</td></tr></tbody></table><table-wrap-foot><p>Aβ, beta-amyloid; APOE, apolipoprotein E; ARWMC, Age-Related White Matter Changes scale; BBB, blood–brain barrier; CSF, cerebrospinal fluid; MMSE, the Mini-Mental State Examination; SD, standard deviation; sVCAM-1, soluble vascular cell adhesion molecule-1.</p></table-wrap-foot></table-wrap><fig id='F1' position='float'><label>Figure 1</label><caption><p><bold>Cause of death.</bold> Sixty-five different ICD-10 codes were found on the death certificates. These have been grouped into these 11 categories.</p></caption><graphic xlink:href='alzrt271-1'></graphic></fig><p><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The concomitant diseases and medications are shown in Table <xref rid='T2' ref-type='table'>2</xref>.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Folate or vitamin B<sub>12</sub> deficiency was the most common diagnosis (41%), followed by hypertension (32%), gastrointestinal diseases (30%), and heart disease (26%).</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The most common drugs were antidepressants (43%), followed by cardiovascular drugs (34%) and antipsychotics/sedatives (31%).</s></p><table-wrap position='float' id='T2'><label>Table 2</label><caption><p>Prevalence of concomitant diseases and medications</p></caption><table border='1' rules='groups' frame='hsides'><colgroup><col align='left'></col><col align='left'></col></colgroup><thead valign='top'><tr><th align='left'><bold>Disease category</bold></th><th align='left'><bold>Prevalence (%)</bold></th></tr></thead><tbody valign='top'><tr><td valign='bottom' align='left'>Folate or vitamin B<sub>12</sub> deficiency<hr></hr></td><td valign='bottom' align='left'>41<hr></hr></td></tr><tr><td valign='bottom' align='left'>All other diseases<hr></hr></td><td valign='bottom' align='left'>39<hr></hr></td></tr><tr><td valign='bottom' align='left'>Hypertension<hr></hr></td><td valign='bottom' align='left'>32<hr></hr></td></tr><tr><td valign='bottom' align='left'>Gastrointestinal diseases<hr></hr></td><td valign='bottom' align='left'>30<hr></hr></td></tr><tr><td valign='bottom' align='left'>Heart disease<hr></hr></td><td valign='bottom' align='left'>26<hr></hr></td></tr><tr><td valign='bottom' align='left'>Hypotension<hr></hr></td><td valign='bottom' align='left'>18<hr></hr></td></tr><tr><td valign='bottom' align='left'>Thyroid diseases<hr></hr></td><td valign='bottom' align='left'>17<hr></hr></td></tr><tr><td valign='bottom' align='left'>Hypercholesterolemia<hr></hr></td><td valign='bottom' align='left'>13<hr></hr></td></tr><tr><td valign='bottom' align='left'>Pulmonary diseases<hr></hr></td><td valign='bottom' align='left'>11<hr></hr></td></tr><tr><td valign='bottom' align='left'>Major depression or anxiety disorders<hr></hr></td><td valign='bottom' align='left'>9<hr></hr></td></tr><tr><td valign='bottom' align='left'>Diabetes<hr></hr></td><td valign='bottom' align='left'>8<hr></hr></td></tr><tr><td valign='bottom' align='left'>Liver or kidney diseases<hr></hr></td><td valign='bottom' align='left'>5<hr></hr></td></tr><tr><td valign='bottom' align='left'><bold>Medications</bold><hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Antidepressants<hr></hr></td><td valign='bottom' align='left'>43<hr></hr></td></tr><tr><td valign='bottom' align='left'>Cardiovascular drugs<hr></hr></td><td valign='bottom' align='left'>34<hr></hr></td></tr><tr><td valign='bottom' align='left'>Platelet-aggregation inhibitors<hr></hr></td><td valign='bottom' align='left'>32<hr></hr></td></tr><tr><td valign='bottom' align='left'>Antipsychotics/sedatives<hr></hr></td><td valign='bottom' align='left'>31<hr></hr></td></tr><tr><td valign='bottom' align='left'>Analgesics (except aspirin and NSAIDs)<hr></hr></td><td valign='bottom' align='left'>13<hr></hr></td></tr><tr><td valign='bottom' align='left'>Thyroxine<hr></hr></td><td valign='bottom' align='left'>12<hr></hr></td></tr><tr><td valign='bottom' align='left'>Serum lipid-reducing agents<hr></hr></td><td valign='bottom' align='left'>12<hr></hr></td></tr><tr><td valign='bottom' align='left'>Antacids<hr></hr></td><td valign='bottom' align='left'>9<hr></hr></td></tr><tr><td valign='bottom' align='left'>Estrogen therapy<hr></hr></td><td valign='bottom' align='left'>7<hr></hr></td></tr><tr><td align='left'>NSAIDs</td><td align='left'>2</td></tr></tbody></table><table-wrap-foot><p>NSAIDs, nonsteroidal antiinflammatory drugs.</p></table-wrap-foot></table-wrap></sec><sec><title>Prediction of mortality: main analyses</title><p><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The significant variables for predicting death caused by dementia were the MMSE score (HR, 0.51; 95% CI, 0.43–0.61), Evans ratio (HR, 1.38; 95% CI, 1.12–1.70), sVCAM-1 (HR, 1.32; 95% CI, 1.07–1.64), and temporal horn ratio (HR, 1.23; 95% CI, 1.02–1.49), which are shown in Table <xref rid='T3' ref-type='table'>3</xref> (that is, the independent risk factors for death caused by AD were frontal and medial temporal atrophy, high levels of cerebral inflammation, and, most significantly, low cognitive status at baseline).</s><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Note that all HRs are based on <italic>z</italic> scores, which allows a head-to-head comparison of the HRs of the variables.</s></p><table-wrap position='float' id='T3'><label>Table 3</label><caption><p>Risk factors for AD mortality (multivariate Cox regression analyses)</p></caption><table border='1' rules='groups' frame='hsides'><colgroup><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col></colgroup><thead valign='top'><tr><th align='left'><bold>Cause of death</bold></th><th align='left'><bold>Significant variables</bold></th><th align='left'><bold><italic>P </italic></bold><bold>value</bold></th><th align='left'><bold>HR (95% </bold><bold>CI)</bold></th></tr></thead><tbody valign='top'><tr><td valign='bottom' align='left'>Dementia<hr></hr></td><td valign='bottom' align='left'>Cognition<hr></hr></td><td valign='bottom' align='left'>&lt;0.001<hr></hr></td><td valign='bottom' align='left'>0.51 (0.43–0.61)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frontal atrophy<hr></hr></td><td valign='bottom' align='left'>0.003<hr></hr></td><td valign='bottom' align='left'>1.38 (1.12–1.70)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Inflammation<hr></hr></td><td valign='bottom' align='left'>0.010<hr></hr></td><td valign='bottom' align='left'>1.32 (1.07–1.64)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Medial temporal atrophy<hr></hr></td><td valign='bottom' align='left'>0.032<hr></hr></td><td valign='bottom' align='left'>1.23 (1.02–1.49)<hr></hr></td></tr><tr><td rowspan='2' valign='top' align='left'>Dementia and related causes<hr></hr></td><td valign='bottom' align='left'>Cognition<hr></hr></td><td valign='bottom' align='left'>&lt;0.001<hr></hr></td><td valign='bottom' align='left'>0.58 (0.50–0.66)<hr></hr></td></tr><tr><td valign='bottom' align='left'>Frontal atrophy<hr></hr></td><td valign='bottom' align='left'>&lt;0.001<hr></hr></td><td valign='bottom' align='left'>1.33 (1.13–1.57)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Age<hr></hr></td><td valign='bottom' align='left'>0.019<hr></hr></td><td valign='bottom' align='left'>1.23 (1.04–1.46)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Inflammation<hr></hr></td><td valign='bottom' align='left'>0.024<hr></hr></td><td valign='bottom' align='left'>1.22 (1.03–1.45)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Vascular lesions<hr></hr></td><td valign='bottom' align='left'>0.036<hr></hr></td><td valign='bottom' align='left'>1.17 (1.01–1.36)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>BBB integrity<hr></hr></td><td valign='bottom' align='left'>0.048<hr></hr></td><td valign='bottom' align='left'>1.16 (1.001–1.34)<hr></hr></td></tr><tr><td valign='bottom' align='left'>All-cause mortality<hr></hr></td><td valign='bottom' align='left'>Cognition<hr></hr></td><td valign='bottom' align='left'>&lt;0.001<hr></hr></td><td valign='bottom' align='left'>0.59 (0.52–0.67)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frontal atrophy<hr></hr></td><td valign='bottom' align='left'>&lt;0.001<hr></hr></td><td valign='bottom' align='left'>1.31 (1.13–1.52)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Age<hr></hr></td><td valign='bottom' align='left'>0.001<hr></hr></td><td valign='bottom' align='left'>1.28 (1.10–1.49)<hr></hr></td></tr><tr><td align='left'> </td><td align='left'>Inflammation</td><td align='left'>0.005</td><td align='left'>1.24 (1.07–1.45)</td></tr></tbody></table><table-wrap-foot><p>All variables described in Risk factors of mortality (Methods) were entered into each of the three models. The continuous variables were converted to <italic>z</italic> scores. Only significant variables are shown in the table. The following variables were not significant in any of the models: CSF Aβ42 and APOE ϵ4/ϵ4 (amyloid pathology), CSF tau and P-tau (tau pathology), cella media index (central atrophy), and sex. BBB integrity, CSF/serum albumin ratio; cognition, MMSE score; CI, confidence interval; frontal atrophy, Evans ratio; HR, hazard ratio; inflammation, sVCAM-1; medial temporal atrophy, temporal horn ratio; vascular lesions, ARWMC (Age-related White Matter Changes scale).</p></table-wrap-foot></table-wrap><p><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>When predicting dementia- and AD-pathology-related causes of death, the significant variables were Evans ratio (HR, 1.33; 95% CI, 1.13–1.57), sVCAM-1 (HR, 1.22; 95% CI, 1.03–1.45), albumin ratio (HR, 1.16, 95% CI, 1.001–1.34), ARWMC score (HR, 1.17; 95% CI, 1.01–1.36); MMSE score (HR, 0.58; 95% CI, 0.50–0.66), and age (HR, 1.23; 95% CI 1.04–1.46) (Table <xref rid='T3' ref-type='table'>3</xref>).</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In addition to frontal atrophy, cerebral inflammation, and cognitive impairment, this model found that cerebrovascular pathology and older age were significant independent predictors for death caused by dementia and related causes.</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> This was probably caused by the vascular origin of most of the AD-related causes of death.</s></p><p><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The model for all-cause mortality revealed the following significant variables: Evans ratio (HR, 1.31; 95% CI, 1.13–1.52), age (HR, 1.28; 95% CI, 1.10–1.49), MMSE score (HR, 0.59; 95% CI, 0.52–0.67), and sVCAM-1 (HR, 1.24; 95% CI, 1.07–1.45) (Table <xref rid='T3' ref-type='table'>3</xref>).</s></p><p><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The variables for amyloid (Aβ42 and APOE ϵ4/ϵ4) and tau (total tau and P-tau) pathology were not significant in any of the models (data not shown).</s></p></sec><sec><title>The effect of comorbidity and medications: subanalyses</title><p><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>No concomitant disease was a risk factor for death caused by dementia (Table <xref rid='T4' ref-type='table'>4</xref>).</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Neither could a concomitant disease predict death caused by dementia and related causes; however, older age was a significant risk factor in this model (HR, 1.04; 95% CI, 1.02–1.07).</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> When predicting all-cause mortality, both older age (HR, 1.04; 95% CI, 1.02–1.07) and hypertension (HR, 1.34; 95% CI, 1.01–1.78) were significant variables (Table <xref rid='T4' ref-type='table'>4</xref>).</s></p><table-wrap position='float' id='T4'><label>Table 4</label><caption><p>Comorbidity and medication risk factors for mortality (multivariate Cox regression analyses)</p></caption><table border='1' rules='groups' frame='hsides'><colgroup><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col></colgroup><thead valign='top'><tr><th align='left'><bold>Risk factors (covariates)</bold></th><th align='left'><bold>Cause of death (dependent variable)</bold></th><th align='left'><bold>Significant variables</bold></th><th align='left'><bold><italic>P </italic></bold><bold>value</bold></th><th align='left'><bold>HR (95% </bold><bold>CI)</bold></th></tr></thead><tbody valign='top'><tr><td valign='bottom' align='left'>Comorbidities<hr></hr></td><td valign='bottom' align='left'>Dementia<hr></hr></td><td valign='bottom' align='left'>No significant variables<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Dementia and related causes<hr></hr></td><td valign='bottom' align='left'>Age<hr></hr></td><td valign='bottom' align='left'>&lt;0.001<hr></hr></td><td valign='bottom' align='left'>1.31 (1.12–1.53)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>All-cause mortality<hr></hr></td><td valign='bottom' align='left'>Age<hr></hr></td><td valign='bottom' align='left'>&lt;0.001<hr></hr></td><td valign='bottom' align='left'>1.30 (1.13–1.50)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Hypertension<hr></hr></td><td valign='bottom' align='left'>0.041<hr></hr></td><td valign='bottom' align='left'>1.34 (1.01–1.78)<hr></hr></td></tr><tr><td valign='bottom' align='left'>Medications<hr></hr></td><td valign='bottom' align='left'>Dementia<hr></hr></td><td valign='bottom' align='left'>No significant variables<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Dementia and related causes<hr></hr></td><td valign='bottom' align='left'>Age<hr></hr></td><td valign='bottom' align='left'>&lt;0.001<hr></hr></td><td valign='bottom' align='left'>1.30 (1.11–1.52)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>All-cause mortality<hr></hr></td><td valign='bottom' align='left'>Age<hr></hr></td><td valign='bottom' align='left'>0.001<hr></hr></td><td valign='bottom' align='left'>1.27 (1.10–1.47)<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Cardiovascular drugs<hr></hr></td><td valign='bottom' align='left'>0.024<hr></hr></td><td valign='bottom' align='left'>1.38 (1.04–1.83)<hr></hr></td></tr><tr><td align='left'> </td><td align='left'> </td><td align='left'>Antipsychotics/sedatives</td><td align='left'>0.036</td><td align='left'>1.36 (1.02–1.81)</td></tr></tbody></table><table-wrap-foot><p>Age was converted to a <italic>z</italic>-score for comparison with the continuous variables shown in Table <xref rid='T3' ref-type='table'>3</xref>. All comorbidities and medications with a prevalence ≥10% (Table <xref rid='T2' ref-type='table'>2</xref>), as well as age and sex, were entered into the Cox regression analyses. Comorbidities and medications were entered separately. HR, hazard ratio.</p></table-wrap-foot></table-wrap><p><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Similarly, no medications were risk factors for death caused by dementia (Table <xref rid='T4' ref-type='table'>4</xref>), and older age was a significant risk factor for death caused by dementia and related causes (HR, 1.04; 95% CI, 1.02–1.07).</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the all-cause model, the following variables were significant (Table <xref rid='T4' ref-type='table'>4</xref>): older age (HR, 1.04; 95% CI, 1.02–1.06), antipsychotics/sedatives (HR, 1.36; 95% CI, 1.02–1.82), and cardiovascular drugs (HR, 1.38; 95% CI, 1.04–1.83).</s></p></sec></sec><sec sec-type='discussion'><title>Discussion</title><p><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>In this 13-year longitudinal study of 247 patients with mild-to-moderate AD, we found that increased cerebral inflammation was the only AD-related pathology that was an independent risk factor for death caused specifically by dementia (Table <xref rid='T3' ref-type='table'>3</xref>).</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Other significant risk factors were low cognitive ability, frontal atrophy, and medial temporal lobe atrophy.</s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Tau, amyloid, or cerebrovascular pathology were not significant variables in the Cox regression model for death caused by dementia.</s></p><p><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>To the best of our knowledge, the present study is the first to show that cerebral inflammation is independently associated with early death in AD.</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Cerebral inflammation, as measured by CSF sVCAM-1 level, was a risk factor for early death in all mortality groups (Table <xref rid='T3' ref-type='table'>3</xref>).</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Previous studies reported that neuroinflammation is involved in the pathogenesis of AD [<xref rid='B18' ref-type='bibr'>18</xref>,<xref rid='B30' ref-type='bibr'>30</xref>-<xref rid='B33' ref-type='bibr'>33</xref>].</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It has been suggested that chronic neuroinflammation represents a risk factor for AD in the elderly through an acceleration of senescence in microglia, with a reduction in their neuroprotective function leading to the formation of senile plaques and neurofibrillary tangles [<xref rid='B34' ref-type='bibr'>34</xref>].</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A recent neuropathologic study found that cerebral inflammation measured as glial response is an essential mechanism that determines which of the patients with a high load of tau and amyloid pathology were demented or nondemented [<xref rid='B19' ref-type='bibr'>19</xref>].</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Thus, inflammation might be a key component in the toxicity of β-amyloid, as many individuals have a high burden of amyloid and tau pathology without any clinical symptoms [<xref rid='B19' ref-type='bibr'>19</xref>].</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Furthermore, Forassi <italic>et al</italic>.</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> [<xref rid='B35' ref-type='bibr'>35</xref>] showed that systemic inflammation is a strong independent risk factor for death in an elderly population.</s></p><p><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The other significant risk factors identified (lower cognitive status, frontal atrophy, and medial temporal lobe atrophy) should probably be interpreted as downstream biomarkers, which reflect the disease duration and disease stage.</s><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Other studies have also found that low cognitive function and atrophy at baseline are significant risk factors for mortality [<xref rid='B36' ref-type='bibr'>36</xref>-<xref rid='B39' ref-type='bibr'>39</xref>].</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Frontal atrophy was a stronger predictor than medial temporal atrophy (Table <xref rid='T3' ref-type='table'>3</xref>), possibly because medial temporal atrophy is an earlier step in the disease process, whereas frontal atrophy occurs later, as an indicator of end-stage dementia [<xref rid='B27' ref-type='bibr'>27</xref>].</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Another explanation could be that AD patients with frontal lobe degeneration constitute a subset of AD with a more rapid disease progression.</s><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This assumption is supported by previous results, that revealed that tests of frontal cognitive function, but not those of parietal and temporal function, independently predicted a more rapid AD progression [<xref rid='B40' ref-type='bibr'>40</xref>].</s></p><p><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>The results of the subanalyses showed that AD-related factors, but not concomitant diseases or medications, caused early death in AD (Table <xref rid='T4' ref-type='table'>4</xref>).</s><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This was further supported by the fact that neither older age nor male sex predicted specific-cause death (Table <xref rid='T4' ref-type='table'>4</xref>), even though they are regarded as traditional predictors of death among elderly individuals.</s></p><p><s sid='137'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Neuroleptic/sedative drugs were associated with early death in the all-cause model, which was in line with previous studies that showed that psychotic symptoms and/or neuroleptic drugs increase mortality rates [<xref rid='B4' ref-type='bibr'>4</xref>,<xref rid='B41' ref-type='bibr'>41</xref>,<xref rid='B42' ref-type='bibr'>42</xref>].</s><s sid='138'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean survival time of 6.4 years found here was in agreement with a large review of 42 studies on AD mortality [<xref rid='B43' ref-type='bibr'>43</xref>].</s><s sid='139'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Large differences are found in the prevalence of death causes, but overall, pneumonia and dementia have been reported most commonly [<xref rid='B3' ref-type='bibr'>3</xref>,<xref rid='B11' ref-type='bibr'>11</xref>,<xref rid='B13' ref-type='bibr'>13</xref>,<xref rid='B44' ref-type='bibr'>44</xref>], which differs somewhat from the results of the present study (Figure <xref rid='F1' ref-type='fig'>1</xref>).</s><s sid='140'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> We believe this can be explained by the manner in which the cause of death was entered on the death certificate, rather than by an actual difference in death causes.</s><s sid='141'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> If no other specific diagnosis was apparent at the time of death, the attending physician most likely regarded dementia as the cause of death.</s></p><p><s sid='142'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>One of the strengths of this study was that it constitutes the world’s longest longitudinal study with CSF biomarkers of AD, which ensures a high diagnostic accuracy and a low number of censored cases (patients still alive at follow-up).</s><s sid='143'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We also examined predictors of specific-cause death due to dementia, and not only all-cause death, which is essential when trying to map key mechanisms of mortality in AD.</s><s sid='144'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Other advantages of our study included the multivariate design of the analysis, which allowed us to examine independent effects of the most common pathologies and hallmarks of AD, and the inclusion of patients from a routine clinical setting.</s></p><p><s sid='145'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>We chose to measure cerebral inflammation by using sVCAM-1 levels in the CSF, based on previous validating studies [<xref rid='B45' ref-type='bibr'>45</xref>-<xref rid='B50' ref-type='bibr'>50</xref>]. sVCAM-1 is a cell-surface molecule that regulates leukocyte migration and is activated by proinflammatory factors such as cytokines and interleukins [<xref rid='B49' ref-type='bibr'>49</xref>].</s><s sid='146'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Moreover, it has been associated with glial activation (expressed on astrocytes) [<xref rid='B47' ref-type='bibr'>47</xref>].</s><s sid='147'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Numerous studies have associated increased levels of sVCAM-1 with several neuroinflammatory conditions, and it has been significantly correlated with inflammatory cerebral lesions assessed by using contrast MRI [<xref rid='B45' ref-type='bibr'>45</xref>-<xref rid='B50' ref-type='bibr'>50</xref>]. sVCAM-1 is also a well-proven marker of endothelial dysfunction and has been associated with atherosclerosis [<xref rid='B51' ref-type='bibr'>51</xref>] and small-vessel disease [<xref rid='B52' ref-type='bibr'>52</xref>].</s><s sid='148'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, based on our results, we believe that sVCAM-1 is related more directly to neuroinflammation, rather than to cerebrovascular pathology, as sVCAM-1, not vascular lesions and BBB integrity, was an independent significant variable in the main analysis performed to predict death caused by dementia (Table <xref rid='T3' ref-type='table'>3</xref>).</s><s sid='149'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Vascular lesions and BBB integrity were, however, separately significant when examining death also caused by cerebrovascular disorders, which validates them as adequate markers of vascular pathology in this data set.</s></p><p><s sid='150'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>To warrant our conclusions, the results of this exploratory study should be tested in larger longitudinal cohorts including additional factors that are associated with shorter survival (for example, diabetes) and using other markers of inflammation such as IL-1 on either the protein or mRNA level.</s></p></sec><sec sec-type='conclusions'><title>Conclusions</title><p><s sid='151'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>We found that cerebral inflammation measured by using sVCAM-1 levels in the CSF was an independent risk factor for early death in AD.</s><s sid='152'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> A more-advanced disease stage was also a risk factor, as assessed by using the significantly independent variables of global cognition and medial temporal and frontal atrophy.</s><s sid='153'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The biomarkers of tau or amyloid were not significant risk factors, and cerebrovascular pathology was only a significant risk factor when including death caused by vascular disorders and infections.</s><s sid='154'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> This is the first study of its kind, and further research is needed to confirm these findings.</s><s sid='155'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> As early death is linked to a rapid disease progression [<xref rid='B53' ref-type='bibr'>53</xref>], our results could have implications for estimating the malignancy or toxicity of the AD process, and for selecting correct targets in future clinical trials of disease-modifying therapies.</s></p></sec><sec><title>Abbreviations</title><p>APOE: Apolipoprotein E; ARWMC: age-related white-matter changes; Aβ: amyloid beta; Aβ42: the 42-amino-acid isoform of amyloid-β<sub>1–42</sub>; BBB: blood–brain barrier; COPD: chronic obstructive pulmonary disease; CSF: cerebrospinal fluid; CT: computed tomography; ELISA: enzyme-linked immunosorbent assay; HR: hazard ratio; ICD-10: the tenth revision of the International Classification of Disease; LR: likelihood ratio; MMSE: Mini-Mental State Examination; MRI: magnetic resonance imaging; P-tau: Tau phosphorylated at Thr181; SD: standard deviation; sVCAM-1: soluble vascular cell-adhesion molecule 1.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors’ contributions</title><p>KN, data collection, writing of manuscript draft, critical manuscript revision, and final approval of the manuscript. CW, review of statistical analysis, critical manuscript revision, and final approval of the manuscript. YZ, assessment of atrophy measures, critical manuscript revision, and final approval of the manuscript. LOW, supervision, critical manuscript revision, and final approval of the manuscript. SP, conception and design, supervision, data collection and analysis, assessment of cerebrovascular lesions, writing of manuscript draft, critical manuscript revision, and final approval of the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>The study was supported by funding from the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s Disease) at Lund University, and by the Regional agreement on medical training and clinical research (ALF) between the Skåne County Council and Lund University, Sweden.</p></sec><ref-list><ref id='B1'><mixed-citation publication-type='journal'><name><surname>Jagger</surname><given-names>C</given-names></name><name><surname>Andersen</surname><given-names>K</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name><name><surname>Copeland</surname><given-names>JR</given-names></name><name><surname>Helmer</surname><given-names>C</given-names></name><name><surname>Baldereschi</surname><given-names>M</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>Lobo</surname><given-names>A</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><article-title>Prognosis with dementia in Europe: a collaborative study of population-based cohorts: Neurologic Diseases in the Elderly Research Group</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>S16</fpage><lpage>S20</lpage><pub-id pub-id-type='pmid'>10854356</pub-id></mixed-citation></ref><ref id='B2'><mixed-citation publication-type='journal'><name><surname>Lonnroos</surname><given-names>E</given-names></name><name><surname>Kyyronen</surname><given-names>P</given-names></name><name><surname>Bell</surname><given-names>JS</given-names></name><name><surname>van der Cammen</surname><given-names>TJ</given-names></name><name><surname>Hartikainen</surname><given-names>S</given-names></name><article-title>Risk of death among persons with Alzheimer’s disease: a national register-based nested case–control study</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>33</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type='pmid'>22914589</pub-id></mixed-citation></ref><ref id='B3'><mixed-citation publication-type='journal'><name><surname>Ganguli</surname><given-names>M</given-names></name><name><surname>Dodge</surname><given-names>HH</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Pandav</surname><given-names>RS</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><article-title>Alzheimer disease and mortality: a 15-year epidemiological study</article-title><source>Arch Neurol</source><year>2005</year><volume>62</volume><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type='pmid'>15883266</pub-id></mixed-citation></ref><ref id='B4'><mixed-citation publication-type='journal'><name><surname>Tsai</surname><given-names>PH</given-names></name><name><surname>Chen</surname><given-names>SP</given-names></name><name><surname>Lin</surname><given-names>KN</given-names></name><name><surname>Wang</surname><given-names>PN</given-names></name><name><surname>Wang</surname><given-names>HC</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Hong</surname><given-names>CJ</given-names></name><name><surname>Liu</surname><given-names>HC</given-names></name><article-title>Survival of ethnic Chinese with Alzheimer’s disease: a 5-year longitudinal study in Taiwan</article-title><source>J Geriatr Psychiatry Neurol</source><year>2007</year><volume>20</volume><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type='pmid'>17712101</pub-id></mixed-citation></ref><ref id='B5'><mixed-citation publication-type='journal'><name><surname>Arrighi</surname><given-names>HM</given-names></name><name><surname>Neumann</surname><given-names>PJ</given-names></name><name><surname>Lieberburg</surname><given-names>IM</given-names></name><name><surname>Townsend</surname><given-names>RJ</given-names></name><article-title>Lethality of Alzheimer disease and its impact on nursing home placement</article-title><source>Alzheimer Dis Assoc Disord</source><year>2010</year><volume>24</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type='pmid'>19568155</pub-id></mixed-citation></ref><ref id='B6'><mixed-citation publication-type='journal'><collab>Association As</collab><article-title>Alzheimer’s disease facts and figures</article-title><source>Alzheimers Dement</source><year>2012</year><volume>8</volume><fpage>131</fpage><lpage>168</lpage><pub-id pub-id-type='pmid'>22404854</pub-id></mixed-citation></ref><ref id='B7'><mixed-citation publication-type='journal'><name><surname>Aguero-Torres</surname><given-names>H</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Viitanen</surname><given-names>M</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><article-title>Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases</article-title><source>J Clin Epidemiol</source><year>1999</year><volume>52</volume><fpage>737</fpage><lpage>743</lpage><pub-id pub-id-type='pmid'>10465318</pub-id></mixed-citation></ref><ref id='B8'><mixed-citation publication-type='journal'><name><surname>Eaker</surname><given-names>ED</given-names></name><name><surname>Vierkant</surname><given-names>RA</given-names></name><name><surname>Mickel</surname><given-names>SF</given-names></name><article-title>Predictors of nursing home admission and/or death in incident Alzheimer’s disease and other dementia cases compared to controls: a population-based study</article-title><source>J Clin Epidemiol</source><year>2002</year><volume>55</volume><fpage>462</fpage><lpage>468</lpage><pub-id pub-id-type='pmid'>12007549</pub-id></mixed-citation></ref><ref id='B9'><mixed-citation publication-type='journal'><name><surname>Brookmeyer</surname><given-names>R</given-names></name><name><surname>Corrada</surname><given-names>MM</given-names></name><name><surname>Curriero</surname><given-names>FC</given-names></name><name><surname>Kawas</surname><given-names>C</given-names></name><article-title>Survival following a diagnosis of Alzheimer disease</article-title><source>Arch Neurol</source><year>2002</year><volume>59</volume><fpage>1764</fpage><lpage>1767</lpage><pub-id pub-id-type='pmid'>12433264</pub-id></mixed-citation></ref><ref id='B10'><mixed-citation publication-type='journal'><name><surname>Helzner</surname><given-names>EP</given-names></name><name><surname>Scarmeas</surname><given-names>N</given-names></name><name><surname>Cosentino</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>MX</given-names></name><name><surname>Schupf</surname><given-names>N</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name><article-title>Survival in Alzheimer disease: a multiethnic, population-based study of incident cases</article-title><source>Neurology</source><year>2008</year><volume>71</volume><fpage>1489</fpage><lpage>1495</lpage><pub-id pub-id-type='pmid'>18981370</pub-id></mixed-citation></ref><ref id='B11'><mixed-citation publication-type='journal'><name><surname>Thomas</surname><given-names>BM</given-names></name><name><surname>Starr</surname><given-names>JM</given-names></name><name><surname>Whalley</surname><given-names>LJ</given-names></name><article-title>Death certification in treated cases of presenile Alzheimer’s disease and vascular dementia in Scotland</article-title><source>Age Ageing</source><year>1997</year><volume>26</volume><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type='pmid'>9351485</pub-id></mixed-citation></ref><ref id='B12'><mixed-citation publication-type='journal'><name><surname>Ueki</surname><given-names>A</given-names></name><name><surname>Shinjo</surname><given-names>H</given-names></name><name><surname>Shimode</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name><article-title>Factors associated with mortality in patients with early-onset Alzheimer’s disease: a five-year longitudinal study</article-title><source>Int J Geriatr Psychiatry</source><year>2001</year><volume>16</volume><fpage>810</fpage><lpage>815</lpage><pub-id pub-id-type='pmid'>11536348</pub-id></mixed-citation></ref><ref id='B13'><mixed-citation publication-type='journal'><name><surname>Brunnstrom</surname><given-names>HR</given-names></name><name><surname>Englund</surname><given-names>EM</given-names></name><article-title>Cause of death in patients with dementia disorders</article-title><source>Eur J Neurol</source><year>2009</year><volume>16</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type='pmid'>19170740</pub-id></mixed-citation></ref><ref id='B14'><mixed-citation publication-type='journal'><name><surname>Mölsä</surname><given-names>PK</given-names></name><name><surname>Marttila</surname><given-names>RJ</given-names></name><name><surname>Rinne</surname><given-names>UK</given-names></name><article-title>Survival and cause of death in Alzheimer’s disease and multi-infarct dementia</article-title><source>Acta Neurol Scand</source><year>1986</year><volume>74</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type='pmid'>3776457</pub-id></mixed-citation></ref><ref id='B15'><mixed-citation publication-type='journal'><name><surname>Ryan</surname><given-names>D</given-names></name><article-title>Death in dementia: a study of causes of death in dementia patients and their spouses</article-title><source>Int J Geriatr Psychiatry</source><year>1992</year><volume>7</volume><fpage>465</fpage><lpage>472</lpage></mixed-citation></ref><ref id='B16'><mixed-citation publication-type='journal'><name><surname>Iadecola</surname><given-names>C</given-names></name><article-title>The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia</article-title><source>Acta Neuropathol</source><year>2010</year><volume>120</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type='pmid'>20623294</pub-id></mixed-citation></ref><ref id='B17'><mixed-citation publication-type='journal'><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Vemuri</surname><given-names>P</given-names></name><name><surname>Wiste</surname><given-names>HJ</given-names></name><name><surname>Weigand</surname><given-names>SD</given-names></name><name><surname>Lesnick</surname><given-names>TG</given-names></name><name><surname>Pankratz</surname><given-names>VS</given-names></name><name><surname>Donohue</surname><given-names>MC</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers</article-title><source>Lancet Neurol</source><year>2013</year><volume>12</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type='pmid'>23332364</pub-id></mixed-citation></ref><ref id='B18'><mixed-citation publication-type='journal'><name><surname>Zotova</surname><given-names>E</given-names></name><name><surname>Nicoll</surname><given-names>JA</given-names></name><name><surname>Kalaria</surname><given-names>R</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Boche</surname><given-names>D</given-names></name><article-title>Inflammation in Alzheimer’s disease: relevance to pathogenesis and therapy</article-title><source>Alzheimers Res Ther</source><year>2010</year><volume>2</volume><fpage>1</fpage><pub-id pub-id-type='pmid'>20122289</pub-id></mixed-citation></ref><ref id='B19'><mixed-citation publication-type='journal'><name><surname>Perez-Nievas</surname><given-names>BG</given-names></name><name><surname>Stein</surname><given-names>TD</given-names></name><name><surname>Tai</surname><given-names>HC</given-names></name><name><surname>Dols-Icardo</surname><given-names>O</given-names></name><name><surname>Scotton</surname><given-names>TC</given-names></name><name><surname>Barroeta-Espar</surname><given-names>I</given-names></name><name><surname>Fernandez-Carballo</surname><given-names>L</given-names></name><name><surname>de Munain</surname><given-names>EL</given-names></name><name><surname>Perez</surname><given-names>J</given-names></name><name><surname>Marquie</surname><given-names>M</given-names></name><name><surname>Serrano-Pozo</surname><given-names>A</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Lowe</surname><given-names>V</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Ikonomovic</surname><given-names>MD</given-names></name><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Klunk</surname><given-names>W</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Gomez-Isla</surname><given-names>T</given-names></name><article-title>Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology</article-title><source>Brain</source><year>2013</year><volume>136</volume><fpage>2510</fpage><lpage>2526</lpage><pub-id pub-id-type='pmid'>23824488</pub-id></mixed-citation></ref><ref id='B20'><mixed-citation publication-type='journal'><name><surname>Nielsen</surname><given-names>HM</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Janciauskiene</surname><given-names>SM</given-names></name><article-title>Soluble adhesion molecules and angiotensin-converting enzyme in dementia</article-title><source>Neurobiol Dis</source><year>2007</year><volume>26</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type='pmid'>17270454</pub-id></mixed-citation></ref><ref id='B21'><mixed-citation publication-type='journal'><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name><article-title>Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type='pmid'>6610841</pub-id></mixed-citation></ref><ref id='B22'><mixed-citation publication-type='book'><collab>World Health Organization</collab><source>Manual of the International Statistical Classification of Diseases and Health Related Problems. 10th revision</source><year>1992</year><publisher-name>Geneva, Switzerland: World Health Organization</publisher-name></mixed-citation></ref><ref id='B23'><mixed-citation publication-type='journal'><name><surname>Olsson</surname><given-names>A</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>De Meyer</surname><given-names>G</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Holmberg</surname><given-names>B</given-names></name><name><surname>Rosengren</surname><given-names>L</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>Simultaneous measurement of beta-amyloid (1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology</article-title><source>Clin Chem</source><year>2005</year><volume>51</volume><fpage>336</fpage><lpage>345</lpage><pub-id pub-id-type='pmid'>15563479</pub-id></mixed-citation></ref><ref id='B24'><mixed-citation publication-type='journal'><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><article-title>Cerebrospinal fluid and plasma biomarkers in Alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2010</year><volume>6</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type='pmid'>20157306</pub-id></mixed-citation></ref><ref id='B25'><mixed-citation publication-type='journal'><name><surname>Wahlund</surname><given-names>L</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><name><surname>Bronge</surname><given-names>L</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Sjögren</surname><given-names>M</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Ader</surname><given-names>H</given-names></name><name><surname>Leys</surname><given-names>D</given-names></name><name><surname>Pantoni</surname><given-names>L</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Erkinjuntti</surname><given-names>T</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><article-title>A new rating scale for age-related white matter changes applicable to MRI and CT</article-title><source>Stroke</source><year>2001</year><volume>32</volume><fpage>1318</fpage><lpage>1322</lpage><pub-id pub-id-type='pmid'>11387493</pub-id></mixed-citation></ref><ref id='B26'><mixed-citation publication-type='journal'><name><surname>Palmqvist</surname><given-names>S</given-names></name><name><surname>Sarwari</surname><given-names>A</given-names></name><name><surname>Wattmo</surname><given-names>C</given-names></name><name><surname>Bronge</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wahlund</surname><given-names>LO</given-names></name><name><surname>Nagga</surname><given-names>K</given-names></name><article-title>Association between subcortical lesions and behavioral and psychological symptoms in patients with Alzheimer’s disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2011</year><volume>32</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type='pmid'>22343788</pub-id></mixed-citation></ref><ref id='B27'><mixed-citation publication-type='journal'><name><surname>Whitwell</surname><given-names>JL</given-names></name><article-title>Progression of atrophy in Alzheimer’s disease and related disorders</article-title><source>Neurotox Res</source><year>2010</year><volume>18</volume><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type='pmid'>20352396</pub-id></mixed-citation></ref><ref id='B28'><mixed-citation publication-type='journal'><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Wattmo</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Aspelin</surname><given-names>P</given-names></name><name><surname>Wahlund</surname><given-names>LO</given-names></name><article-title>Usefulness of computed tomography linear measurements in diagnosing Alzheimer’s disease</article-title><source>Acta Radiol</source><year>2008</year><volume>49</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type='pmid'>18210318</pub-id></mixed-citation></ref><ref id='B29'><mixed-citation publication-type='journal'><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name><article-title>“Mini-mental state:” a practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type='pmid'>1202204</pub-id></mixed-citation></ref><ref id='B30'><mixed-citation publication-type='journal'><name><surname>Eikelenboom</surname><given-names>P</given-names></name><name><surname>Hoozemans</surname><given-names>JJ</given-names></name><name><surname>Veerhuis</surname><given-names>R</given-names></name><name><surname>van Exel</surname><given-names>E</given-names></name><name><surname>Rozemuller</surname><given-names>AJ</given-names></name><name><surname>van Gool</surname><given-names>WA</given-names></name><article-title>Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer’s disease</article-title><source>Alzheimers Res Ther</source><year>2012</year><volume>4</volume><fpage>15</fpage><pub-id pub-id-type='pmid'>22647384</pub-id></mixed-citation></ref><ref id='B31'><mixed-citation publication-type='journal'><name><surname>Krstic</surname><given-names>D</given-names></name><name><surname>Knuesel</surname><given-names>I</given-names></name><article-title>Deciphering the mechanism underlying late-onset Alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2013</year><volume>9</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type='pmid'>23183882</pub-id></mixed-citation></ref><ref id='B32'><mixed-citation publication-type='journal'><name><surname>McGeer</surname><given-names>PL</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><article-title>Local neuroinflammation and the progression of Alzheimer’s disease</article-title><source>J Neurovirol</source><year>2002</year><volume>8</volume><fpage>529</fpage><lpage>538</lpage><pub-id pub-id-type='pmid'>12476347</pub-id></mixed-citation></ref><ref id='B33'><mixed-citation publication-type='journal'><name><surname>Tan</surname><given-names>ZS</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><article-title>Inflammation in the Alzheimer’s disease cascade: culprit or innocent bystander?</article-title><source>Alzheimers Res Ther</source><year>2010</year><volume>2</volume><fpage>6</fpage><pub-id pub-id-type='pmid'>20388190</pub-id></mixed-citation></ref><ref id='B34'><mixed-citation publication-type='journal'><name><surname>Krstic</surname><given-names>D</given-names></name><name><surname>Madhusudan</surname><given-names>A</given-names></name><name><surname>Doehner</surname><given-names>J</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Notter</surname><given-names>T</given-names></name><name><surname>Imhof</surname><given-names>C</given-names></name><name><surname>Manalastas</surname><given-names>A</given-names></name><name><surname>Hilfiker</surname><given-names>M</given-names></name><name><surname>Pfister</surname><given-names>S</given-names></name><name><surname>Schwerdel</surname><given-names>C</given-names></name><name><surname>Riether</surname><given-names>C</given-names></name><name><surname>Meyer</surname><given-names>U</given-names></name><name><surname>Knuesel</surname><given-names>I</given-names></name><article-title>Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice</article-title><source>J Neuroinflamm</source><year>2012</year><volume>9</volume><fpage>151</fpage></mixed-citation></ref><ref id='B35'><mixed-citation publication-type='journal'><name><surname>Forasassi</surname><given-names>C</given-names></name><name><surname>Golmard</surname><given-names>JL</given-names></name><name><surname>Pautas</surname><given-names>E</given-names></name><name><surname>Piette</surname><given-names>F</given-names></name><name><surname>Myara</surname><given-names>I</given-names></name><name><surname>Raynaud-Simon</surname><given-names>A</given-names></name><article-title>Inflammation and disability as risk factors for mortality in elderly acute care patients</article-title><source>Arch Gerontol Geriatr</source><year>2009</year><volume>48</volume><fpage>406</fpage><lpage>410</lpage><pub-id pub-id-type='pmid'>18456352</pub-id></mixed-citation></ref><ref id='B36'><mixed-citation publication-type='journal'><name><surname>Henneman</surname><given-names>WJ</given-names></name><name><surname>Sluimer</surname><given-names>JD</given-names></name><name><surname>Cordonnier</surname><given-names>C</given-names></name><name><surname>Baak</surname><given-names>MM</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><article-title>MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population</article-title><source>Stroke</source><year>2009</year><volume>40</volume><fpage>492</fpage><lpage>498</lpage><pub-id pub-id-type='pmid'>19109551</pub-id></mixed-citation></ref><ref id='B37'><mixed-citation publication-type='journal'><name><surname>Hotte</surname><given-names>SD</given-names></name><name><surname>Lankers</surname><given-names>D</given-names></name><name><surname>Kissler</surname><given-names>S</given-names></name><name><surname>Freyberger</surname><given-names>HJ</given-names></name><name><surname>Schroder</surname><given-names>SG</given-names></name><article-title>MMSE for survival prognostics in dementia</article-title><source>Psychiatr Prax</source><year>2010</year><volume>37</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type='pmid'>20183772</pub-id></mixed-citation></ref><ref id='B38'><mixed-citation publication-type='journal'><name><surname>Larson</surname><given-names>EB</given-names></name><name><surname>Shadlen</surname><given-names>MF</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>McCormick</surname><given-names>WC</given-names></name><name><surname>Bowen</surname><given-names>JD</given-names></name><name><surname>Teri</surname><given-names>L</given-names></name><name><surname>Kukull</surname><given-names>WA</given-names></name><article-title>Survival after initial diagnosis of Alzheimer disease</article-title><source>Ann Intern Med</source><year>2004</year><volume>140</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type='pmid'>15068977</pub-id></mixed-citation></ref><ref id='B39'><mixed-citation publication-type='journal'><name><surname>Walsh</surname><given-names>JS</given-names></name><name><surname>Welch</surname><given-names>HG</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name><article-title>Survival of outpatients with Alzheimer-type dementia</article-title><source>Ann Intern Med</source><year>1990</year><volume>113</volume><fpage>429</fpage><lpage>434</lpage><pub-id pub-id-type='pmid'>2386336</pub-id></mixed-citation></ref><ref id='B40'><mixed-citation publication-type='journal'><name><surname>Musicco</surname><given-names>M</given-names></name><name><surname>Salamone</surname><given-names>G</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Cravello</surname><given-names>L</given-names></name><name><surname>Fadda</surname><given-names>L</given-names></name><name><surname>Lupo</surname><given-names>F</given-names></name><name><surname>Mosti</surname><given-names>S</given-names></name><name><surname>Perri</surname><given-names>R</given-names></name><name><surname>Palmer</surname><given-names>K</given-names></name><article-title>Neuropsychological predictors of rapidly progressing patients with Alzheimer’s disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2010</year><volume>30</volume><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type='pmid'>20838048</pub-id></mixed-citation></ref><ref id='B41'><mixed-citation publication-type='journal'><name><surname>Scarmeas</surname><given-names>N</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Hadjigeorgiou</surname><given-names>G</given-names></name><name><surname>Papadimitriou</surname><given-names>A</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Sarazin</surname><given-names>M</given-names></name><name><surname>Devanand</surname><given-names>D</given-names></name><name><surname>Honig</surname><given-names>L</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Bell</surname><given-names>K</given-names></name><name><surname>Wegesin</surname><given-names>D</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name><article-title>Delusions and hallucinations are associated with worse outcome in Alzheimer disease</article-title><source>Arch Neurol</source><year>2005</year><volume>62</volume><fpage>1601</fpage><lpage>1608</lpage><pub-id pub-id-type='pmid'>16216946</pub-id></mixed-citation></ref><ref id='B42'><mixed-citation publication-type='journal'><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Dagerman</surname><given-names>KS</given-names></name><name><surname>Insel</surname><given-names>P</given-names></name><article-title>Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials</article-title><source>JAMA</source><year>2005</year><volume>294</volume><fpage>1934</fpage><lpage>1943</lpage><pub-id pub-id-type='pmid'>16234500</pub-id></mixed-citation></ref><ref id='B43'><mixed-citation publication-type='journal'><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Seeher</surname><given-names>K</given-names></name><name><surname>Gibson</surname><given-names>L</given-names></name><article-title>Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia</article-title><source>Int Psychogeriatr</source><year>2012</year><volume>24</volume><fpage>1034</fpage><lpage>1045</lpage><pub-id pub-id-type='pmid'>22325331</pub-id></mixed-citation></ref><ref id='B44'><mixed-citation publication-type='journal'><name><surname>Wachterman</surname><given-names>M</given-names></name><name><surname>Kiely</surname><given-names>DK</given-names></name><name><surname>Mitchell</surname><given-names>SL</given-names></name><article-title>Reporting dementia on the death certificates of nursing home residents dying with end-stage dementia</article-title><source>JAMA</source><year>2008</year><volume>300</volume><fpage>2608</fpage><lpage>2610</lpage><pub-id pub-id-type='pmid'>19066379</pub-id></mixed-citation></ref><ref id='B45'><mixed-citation publication-type='journal'><name><surname>Jaber</surname><given-names>SM</given-names></name><name><surname>Hamed</surname><given-names>EA</given-names></name><name><surname>Hamed</surname><given-names>SA</given-names></name><article-title>Adhesion molecule levels in serum and cerebrospinal fluid in children with bacterial meningitis and sepsis</article-title><source>J Pediatr Neurosci</source><year>2009</year><volume>4</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type='pmid'>21887188</pub-id></mixed-citation></ref><ref id='B46'><mixed-citation publication-type='journal'><name><surname>James</surname><given-names>WG</given-names></name><name><surname>Bullard</surname><given-names>DC</given-names></name><name><surname>Hickey</surname><given-names>MJ</given-names></name><article-title>Critical role of the alpha 4 integrin/VCAM-1 pathway in cerebral leukocyte trafficking in lupus-prone MRL/fas(lpr) mice</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><fpage>520</fpage><lpage>527</lpage><pub-id pub-id-type='pmid'>12496439</pub-id></mixed-citation></ref><ref id='B47'><mixed-citation publication-type='journal'><name><surname>Oh</surname><given-names>JW</given-names></name><name><surname>Van Wagoner</surname><given-names>NJ</given-names></name><name><surname>Rose-John</surname><given-names>S</given-names></name><name><surname>Benveniste</surname><given-names>EN</given-names></name><article-title>Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>4992</fpage><lpage>4999</lpage><pub-id pub-id-type='pmid'>9794436</pub-id></mixed-citation></ref><ref id='B48'><mixed-citation publication-type='journal'><name><surname>Rieckmann</surname><given-names>P</given-names></name><name><surname>Altenhofen</surname><given-names>B</given-names></name><name><surname>Riegel</surname><given-names>A</given-names></name><name><surname>Kallmann</surname><given-names>B</given-names></name><name><surname>Felgenhauer</surname><given-names>K</given-names></name><article-title>Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis</article-title><source>Mult Scler</source><year>1998</year><volume>4</volume><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type='pmid'>9762670</pub-id></mixed-citation></ref><ref id='B49'><mixed-citation publication-type='journal'><name><surname>Singh</surname><given-names>RJ</given-names></name><name><surname>Mason</surname><given-names>JC</given-names></name><name><surname>Lidington</surname><given-names>EA</given-names></name><name><surname>Edwards</surname><given-names>DR</given-names></name><name><surname>Nuttall</surname><given-names>RK</given-names></name><name><surname>Khokha</surname><given-names>R</given-names></name><name><surname>Knauper</surname><given-names>V</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Gavrilovic</surname><given-names>J</given-names></name><article-title>Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3</article-title><source>Cardiovasc Res</source><year>2005</year><volume>67</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type='pmid'>15949468</pub-id></mixed-citation></ref><ref id='B50'><mixed-citation publication-type='journal'><name><surname>Uzawa</surname><given-names>A</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Masuda</surname><given-names>S</given-names></name><name><surname>Kuwabara</surname><given-names>S</given-names></name><article-title>Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood–brain barrier breakdown in neuromyelitis optica</article-title><source>Arch Neurol</source><year>2011</year><volume>68</volume><fpage>913</fpage><lpage>917</lpage><pub-id pub-id-type='pmid'>21747031</pub-id></mixed-citation></ref><ref id='B51'><mixed-citation publication-type='journal'><name><surname>Cybulsky</surname><given-names>MI</given-names></name><name><surname>Iiyama</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Iiyama</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>V</given-names></name><name><surname>Gutierrez-Ramos</surname><given-names>JC</given-names></name><name><surname>Connelly</surname><given-names>PW</given-names></name><name><surname>Milstone</surname><given-names>DS</given-names></name><article-title>A major role for VCAM-1, but not ICAM-1, in early atherosclerosis</article-title><source>J Clin Invest</source><year>2001</year><volume>107</volume><fpage>1255</fpage><lpage>1262</lpage><pub-id pub-id-type='pmid'>11375415</pub-id></mixed-citation></ref><ref id='B52'><mixed-citation publication-type='journal'><name><surname>Rouhl</surname><given-names>RP</given-names></name><name><surname>Damoiseaux</surname><given-names>JG</given-names></name><name><surname>Lodder</surname><given-names>J</given-names></name><name><surname>Theunissen</surname><given-names>RO</given-names></name><name><surname>Knottnerus</surname><given-names>IL</given-names></name><name><surname>Staals</surname><given-names>J</given-names></name><name><surname>Henskens</surname><given-names>LH</given-names></name><name><surname>Kroon</surname><given-names>AA</given-names></name><name><surname>de Leeuw</surname><given-names>PW</given-names></name><name><surname>Tervaert</surname><given-names>JW</given-names></name><name><surname>van Oostenbrugge</surname><given-names>RJ</given-names></name><article-title>Vascular inflammation in cerebral small vessel disease</article-title><source>Neurobiol Aging</source><year>2012</year><volume>33</volume><fpage>1800</fpage><lpage>1806</lpage><pub-id pub-id-type='pmid'>21601314</pub-id></mixed-citation></ref><ref id='B53'><mixed-citation publication-type='journal'><name><surname>Hui</surname><given-names>JS</given-names></name><name><surname>Wilson</surname><given-names>RS</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Bienias</surname><given-names>JL</given-names></name><name><surname>Gilley</surname><given-names>DW</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name><article-title>Rate of cognitive decline and mortality in Alzheimer’s disease</article-title><source>Neurology</source><year>2003</year><volume>61</volume><fpage>1356</fpage><lpage>1361</lpage><pub-id pub-id-type='pmid'>14638955</pub-id></mixed-citation></ref></ref-list></back></article></PAPER>